What is euvolemic hyponatremia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Euvolemic Hyponatremia: Definition and Clinical Characteristics

Euvolemic hyponatremia is a state of low serum sodium (typically <135 mEq/L) occurring in the absence of clinical signs of volume depletion or volume overload, most commonly caused by the syndrome of inappropriate antidiuresis (SIAD, formerly SIADH). 1

Key Diagnostic Features

Euvolemic hyponatremia is characterized by the following laboratory and clinical findings 1:

  • Hyponatremia: Serum sodium <135 mEq/L (some guidelines use <130 mEq/L as the treatment threshold)
  • Hypoosmolality: Plasma osmolality <275 mOsm/kg
  • Inappropriately concentrated urine: Urine osmolality >100 mOsm/kg (typically >300 mOsm/kg in SIAD)
  • Elevated urinary sodium: Urine sodium >20-40 mEq/L
  • Clinical euvolemia: No ascites, edema, or signs of dehydration
  • Normal renal, adrenal, and thyroid function

Pathophysiology

The fundamental mechanism involves impaired free water excretion due to non-osmotic release of antidiuretic hormone (ADH/vasopressin) 1, 2. This leads to:

  • Increased aquaporin expression in renal collecting ducts
  • Water retention disproportionate to sodium retention
  • Dilutional hyponatremia despite normal or expanded total body water
  • Physiologic natriuresis to maintain fluid balance at the expense of serum sodium

Clinical Context and Causes

Most Common Etiology: SIAD

SIAD accounts for the majority of euvolemic hyponatremia cases 3, 4. Common triggers include:

  • Malignancies: Particularly small cell lung cancer (10-45% produce ADH, though only 1-5% become symptomatic) 1
  • Pulmonary disorders: Pneumonia, tuberculosis
  • CNS disorders: Meningitis, encephalitis, stroke
  • Medications: SSRIs, carbamazepine, NSAIDs, thiazides
  • Postoperative states: Pain, nausea, stress all stimulate non-osmotic ADH release 5

Endocrine Causes

While less common (approximately 1.6% of cases), hypothyroidism and adrenal insufficiency must be excluded before diagnosing SIAD 6, 7. These conditions are:

  • Easily treatable and potentially life-threatening if missed
  • Typically present with additional clinical features beyond hyponatremia
  • Resolve within 1-3 days with appropriate hormone replacement 6

Clinical Significance

Symptom Spectrum

Symptoms depend on severity, acuity, and rate of development 8:

  • Mild (125-135 mEq/L): Weakness, confusion, headache, nausea
  • Moderate (120-125 mEq/L): More pronounced neurological symptoms
  • Severe (<120 mEq/L): Seizures, coma, cardiorespiratory distress, death

Chronic Complications

Even mild chronic hyponatremia causes 8:

  • Cognitive impairment and gait disturbances
  • Increased fall risk (23.8% vs 16.4% in normonatremic patients)
  • Higher fracture rates (23.3% vs 17.3% over 7.4 years)
  • Secondary osteoporosis

Prognostic Impact

Hyponatremia is associated with 2, 8:

  • Increased hospital mortality and morbidity
  • Prolonged hospital stays
  • Reduced survival after liver transplantation
  • Poor prognosis in cirrhosis (incorporated into MELD-Na score)

Distinguishing from Other Forms

Volume status assessment is critical to differentiate euvolemic from other types 8:

  • Hypovolemic hyponatremia: Dehydration, orthostasis, low urine sodium (<20 mEq/L typically), requires sodium and volume replacement
  • Hypervolemic hyponatremia: Ascites, edema, heart failure, cirrhosis—characterized by expanded extracellular fluid volume 9, 2

Clinical Mimics

Cerebral salt wasting can mimic SIAD but represents true volume depletion despite similar laboratory findings 10, 3. Key distinction: extracellular fluid volume determination through clinical assessment or invasive monitoring (central venous pressure).

Common Pitfalls

  1. Assuming all euvolemic hyponatremia is SIAD: Always screen for thiazide use and exclude thyroid/adrenal dysfunction first 3, 6

  2. Using 0.9% saline in SIAD: Normal saline acts as a hypotonic solution in SIAD patients due to high urine osmolality, potentially worsening hyponatremia through dual effects—initial correction followed by post-infusion worsening 3

  3. Inadequate workup: Only 69% of patients get thyroid testing and 29% get adrenal testing in real-world practice, potentially missing treatable endocrinopathies 6

  4. Confusing acute vs chronic: Distinguishing hyponatremia present <48 hours (acute) from >48 hours (chronic) is essential for safe correction strategies 3, 11

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.